Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Clovis Oncology (CLVS – Research Report), Veru (VERU – Research Report) and Albireo Pharma (ALBO – Research Report).
Clovis Oncology (CLVS)
H.C. Wainwright analyst Edward White maintained a Hold rating on Clovis Oncology today. The company’s shares closed last Wednesday at $2.18.
According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of
The the analyst consensus on Clovis Oncology is currently a Hold rating.
See Insiders’ Hot Stocks on TipRanks >>
Veru (VERU)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Veru today and set a price target of $24.00. The company’s shares closed last Wednesday at $13.02.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru with a $28.75 average price target, implying a 148.9% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $55.00 price target.
Albireo Pharma (ALBO)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Albireo Pharma today and set a price target of $80.00. The company’s shares closed last Wednesday at $22.75.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma with a $69.00 average price target, implying a 209.0% upside from current levels. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $72.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CLVS:
